id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-316029-z708c3ex	Brunsdon, Priya	Clinical Pharmacology Considerations for Developing Small‐Molecule Treatments for COVID‐19	2020-07-12		.txt	text/plain	4964	264	36	This review will offer key clinical pharmacology considerations for developing small molecules for the treatment of COVID-19 based on the major disease complications that impact drug absorption, distribution, metabolism, and elimination (ADME). Of major concern is sepsis, defined as "life-threatening organ dysfunction caused by a dysregulated host response to infection." 12 In 1 study, septic shock, which is distinguished by persistent hypotension, elevated serum lactate levels, and increased mortality, was a complication in about 6% of severely ill COVID-19 patients. For water-soluble investigational therapies that are intended for administration in the severely ill COVID-19 population, thought should be given to targeting serum drug concentrations and the drug's exposure-response profile when determining if increased doses would be beneficial for patients receiving intravenous fluids. 21 The clinical impact of these potential changes in free drug fractions on investigational therapies that are highly proteinbound is an important consideration when empirically selecting doses for critically ill COVID-19 patients.	./cache/cord-316029-z708c3ex.txt	./txt/cord-316029-z708c3ex.txt